Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, randomized, double-blind placebo controlled study on influenza vaccination in prevention from coronary events in patients with coronary artery disease confirmed by angiography

Next Previous
Trial Profile

Prospective, randomized, double-blind placebo controlled study on influenza vaccination in prevention from coronary events in patients with coronary artery disease confirmed by angiography

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 31 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Acute coronary syndromes; Coronary artery disease; Coronary disorders; Death; Myocardial infarction
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms FLUCAD

Most Recent Events

  • 20 Apr 2010 Actual end date (Dec 2005) added as reported by ClinicalTrials.gov.
  • 02 Sep 2009 The effect of influenza vaccination on coronary ischaemic events overall and in subgroups of participants has been published as an abstract at the Annual Congress of the European Society of Cardiology (ESC 2009).
  • 21 Oct 2006 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top